Aktienanalyse zu Fresenius Medical Care AG (FMS)FMSFresenius Medical Care AG

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers. It operates in the Healthcare sector.

Fresenius Medical Care AG is currently priced at $23.10, which is below several analyst price targets, including $25 from Truist and $32.30 from JPMorgan. However, the stock has a low RSI of 24.23, indicating it is oversold, which could present a buying opportunity. The main risk is its declining U.S. treatment growth, which fell by 0.9%, suggesting potential challenges ahead.